Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Print1
- Print1
- Article Type
- Clinical Trial1
- Clinical Study1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Scand J Rheumatol1
Search Results
Sort by
- BookVerne Harnish and the team at Gazelles.Summary: In this guide, Harnish and his co-authors share practical tools and techniques to help entrepreneurs grow an industry -- dominating business without it killing them -- and actually have fun. Many growth company leaders reach a point where they actually dread adding another customer, employee, or location. It feels like they are just adding more weight to an ever-heavier anchor they are dragging through the sand. To make matters worse, the increased revenues have not turned into more profitability, so at some point they wonder if the journey is worth the effort. This book focuses on the four major decisions every company must get right: People, Strategy, Execution and Cash. The book includes a series of One-Page tools including the One-Page Strategic Plan and the Rockefeller Habits Execution Checklist, which more than 40,000 firms around the globe have used to scale their companies successfully.
Contents:
The overview: People, strategy, execution, cash
The barriers: Leadership, infrastructure, and marketing
The leaders: The FACe and the PACe of the company
The team: Attracting and hiring
The managers (coaches): Keeping and growing (educating) the team
The core: Values, purpose, and competencies
The 7 strata of strategy: The framework for dominating your industry
The one-page strategic plan: The tool for strategic planning
The priority: Focus, finish lines, and fun
The data: Powering prediction
The meeting rhythm: The heartbeat of the organization
The cash: Accelerating cash flow
The accounting: Driving profitability
The power of one: 7 key financial levers
Next steps: 5 things to do now. - ArticleWollheim FA, Hanson A, Laurell CB.Scand J Rheumatol. 1978;7(3):171-6.15 patients with active RA were observed over a 3-month period after starting chloroquine treatment. Clinical condition, plasma levels of chloroquine and levels of 15 individual plasma proteins were checked monthly. Nine patients responded favourably to therapy, 6 failed to respond. The responders had lower initial CRP, orosomucoid and ceruloplasmin levels, whereas their IgA and IgM levels were slightly elevated. Significant reductions in the levels of CRP, haptoglobin, orosomucoid, fibrinogen and ceruloplasmin occurred in the responder group of patients. Alfa1-antitrypsin, antichymotrypsin C3 and C4 levels within the normal range were frequently encountered despite other clear-cut signs of activity. The chloroquine levels did not differ between responders and non-responders, the mean concentrations being 1.04 and 1.6 micromol/l respectively. This study has also demonstrated that in selected cases, despite active joint disease, all acute phase proteins may be normal. Finally, it was obvious that chloroquine, even when inducing remission, only brought about a partial normalization of the plasma protein pattern.